Please assess the completion status of the following clinical trial:

Trial Title: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has paroxysmal, persistent or permanent non-valvular atrial fibrillation (AF)~* Eligible for long term warfarin~* CHADS score \>= 1 \[congestive heart failure (CHF), history of high blood pressure, 75 years of age or older, diabetes, prior stroke or transient ischemic attack (TIA)\]~Exclusion Criteria:~* Contraindicated for warfarin~* Contraindicated for aspirin or clopidogrel (Plavix)~* Congestive heart failure (CHF) Class 4~* Implanted mechanical valve~* Atrial septal or Patent Foramen Ovale (PFO) device~* Platelets \< 100,000 or hemoglobin \< 10~* Left ventricular ejection fraction (LVEF) \< 30%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WATCHMAN (Type: EXPERIMENTAL): Implant of WATCHMAN Left Atrial Appendage Closure Technology
- Warfarin control (Type: ACTIVE_COMPARATOR): Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
- Roll-in (Type: OTHER): Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).